Pancreatic cancer, with its alarming rising incidence, is predicted to become the second deadliest type of solid tumor by 2040, highlighting the urgent need for improved diagnostic and treatment strategies. Despite medical advancements, the five-year survival rate for pancreatic cancer remains about 14%, dropping further when metastasized. This review explores the promise of biomarkers for early detection, personalized treatment, and disease monitoring. Molecular classification of pancreatic cancer into subtypes based on genetic mutations, gene expression, and protein markers guides treatment decisions, potentially improving outcomes. A plethora of clinical trials investigating different strategies are currently ongoing. Targeted therapies, among which those against CLAUDIN 18.2 and inhibitors of Claudin 18.1, have shown promise. Next-generation sequencing (NGS) has emerged as a powerful tool for the comprehensive genomic analysis of pancreatic tumors, revealing unique genetic alterations that drive cancer progression. This allows oncologists to tailor therapies to target specific molecular abnormalities. However, challenges remain, including limited awareness and uptake of biomarker-guided therapies. Continued research into the molecular mechanisms of pancreatic cancer is essential for developing more effective treatments and improving patient survival rates.

The constantly escalating population of cancer survivors worldwide has prompted a focused exploration of their unique needs and experiences within the context of healthcare medicine. This review initiates its analysis inspired by Dr. Lidia Schapira’s insightful keynote conference on the Survivorship 1.0 and Survivorship 2.0 Programs, shedding light on their implementation challenges and setting the stage for a comprehensive analysis of cancer survivorship initiatives. Within the transformed landscape of cancer care, patient-centric strategies embedded in cancer survivorship programs comprising vital elements such as connection, support, and education are presented. While placing cancer recurrence surveillance at the forefront, the review underlines concern regarding the potential oversight of the enduring impact on mental and physical health. Dr. Schapira’s insights further extend into the exploration of mental health challenges faced by survivors, promoting an examination of diverse strategies to address these concerns. Furthermore, the discussion continues toward promising areas of research, notably Precision Medicine’s role in de-escalating cancer therapies, and advocates for measures such as early cancer awareness and timely referrals to supportive services. Highlighting the significance of education, the role of online resources in enhancing the knowledge of healthcare practitioners and future generations in cancer care is then explored. The paper concludes by presenting some of the most prominent global current survivorship programs, identifying critical knowledge gaps in cancer care and projecting future developments aimed at delivering accurate and holistic care, improving the quality of life for survivors, and enhancing both mental and physical well-being. Drawing upon the insights from Dr. Schapira, this review lays the groundwork for a nuanced exploration of cancer survivorship and its multifaceted implications.

Botulinum toxin (Botox) is a neurotoxin drug that is used in a wide range of cosmetic and treatment applications. This literature review provides an overview of the toxin mechanism and its effects. The popularity of toxin usage has been tremendously increasing since it is a minimally invasive procedure. Application of the toxin is primarily utilized for cosmetic purposes, to treat disorders, and as a surgery alternative. The toxin myths such as frozen face have been elaborated, as it is critical to understand the outcomes of the procedure. The toxin is generally considered to be safe, but complications can occur as well, ranging from reactions due to injections to the undesired effects produced by this toxin. Preventive strategies, such as appropriate toxin application techniques, must be considered for safety and prevention. The contraindications to the use of the toxin are also noted in the study.

Hematopoietic stem cell (HSC) therapy remains essential in treating blood disorders, autoimmune diseases, neurodegenerative conditions, and cancers. Despite its potential, challenges arise from the inherent heterogeneity of HSCs and the complexity of their regulatory niche. Recent advancements in single-cell RNA sequencing and chromatin accessibility sequencing have provided deeper insights into HSC markers and chromatin dynamics, highlighting the intricate balance between intrinsic and extrinsic regulatory mechanisms. Zebrafish models have emerged as valuable tools in HSC research, particularly through live imaging and cellular barcoding techniques. These models have allowed us to describe critical interactions between HSCs and embryonic macrophages, involving reactive oxygen species and calreticulin signaling. These are essential for ensuring HSC quality and proper differentiation, with implications for improving HSC transplant outcomes. Furthermore, the review examines clonal hematopoiesis, with a focus on mutations in epigenetic regulators such as DNMT3A, TET2, and ASXL1, which elevate the risk of myelodysplastic syndromes and acute myeloid leukemia. Emerging technologies, including in vivo cellular barcoding and CRISPR-Cas9 gene editing, are being investigated to enhance clonal diversity and target specific mutations, offering potential strategies to mitigate these risks. Additionally, macrophages play a pivotal role in maintaining HSC clonality and ensuring niche localization. Interactions mediated by factors such as VCAM-1 and CXCL12/CXCR4 signaling are crucial for HSC homing and the stress response, opening new therapeutic avenues for enhancing HSC transplantation success and addressing clonal hematopoiesis. This review synthesizes findings from zebrafish models, cutting-edge sequencing technologies, and novel therapeutic strategies, offering a comprehensive framework for advancing HSC biology and improving clinical outcomes in stem cell therapy and the treatment of hematologic diseases.

Ultraviolet (UV) radiation is a known environmental carcinogen whose adverse effects continually contribute to the global burden of disease. One of its brutal effects manifests in the form of skin cancers – namely, basal cell carcinoma, squamous cell carcinoma, and melanoma, its more aggressive but rare counterpart. UV rays exert their effect by direct deoxyribonucleic acid (DNA) damage, diminishing the body’s natural protective repair mechanisms, paving the way for transforming healthy cells into cancerous ones and increasing their metastatic potential. This includes the transformation of typically protective melanin from an antioxidant to a pro-oxidant, inducing oxidative stress and leading to DNA damage in melanocytes. This damage disrupts key signaling pathways such as mitogen-activated protein kinase (MAPK), B-raf proto-oncogene, serine/threonine kinase (BRAF), rat sarcoma viral oncogene homolog (RAS), contributing significantly to melanoma genesis. Treatment strategies target elements involved in these pathways by different mechanisms, such as boosting immune cell components, inducing programmed cell death (apoptosis), inhibiting DNA synthesis pathways, and halting tumor progression, to name a few. The use of novel drugs that target the melanocortin-1 receptor pathway, toll-like receptor 4, and non-coding ribonucleic acid, as well as innovative therapies such as photodynamic therapy, reflects advancements in skin cancer treatment. The prevalence of melanoma steadily rises annually, prompting newer and more targeted approaches to medicine and education regarding skin protection. This literature review summarizes current knowledge regarding pharmacological approaches to skin cancer, focusing on complex molecular mechanisms affected by UV-induced damage. Rising prevalence and advancements in treatment modalities have warranted attention on this topic.